- Home
- HSLV vs OLMA Comparison
HSLV vs OLMA Comparison
Compare HSLV & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSLV | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 893.0M | 1.1B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HSLV | OLMA |
|---|---|---|
| Price | $5.17 | $10.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 361.3K | ★ 941.3K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.88 | $5.29 |
| 52 Week High | $6.77 | $36.26 |
Technical Indicators
Market Signals| Indicator | HSLV | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 38.00 |
| Support Level | $5.08 | $7.79 |
| Resistance Level | $5.28 | $12.61 |
| Average True Range (ATR) | 0.23 | 0.65 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 72.73 | 26.50 |
Price Performance
Historical ComparisonAbout HSLV Highlander Silver Corp. Common Shares
Highlander Silver Corp. is a mineral exploration company engaged in the acquisition, exploration and evaluation of mineral properties located in Peru. It is focused on advancing the bonanza grade San Luis gold-silver project that is located in Central Peru. The company has determined that it has one operating segment, being the exploration of mineral properties.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.